title: IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.
abstract: Recent studies have reported that APC can present particulate exogenous Ag in the context of class I MHC to CD8+ CTL, and our laboratory demonstrated that IL-3 could enhance CTL generation to exogenous Ag. In this paper, we wished to determine whether presentation of particulate Ag could be enhanced by IL-3. A T cell hybridoma, B3Z86/90.14 (B3Z) restricted to Ova/Kb, was used as an indicator for presentation of particulate Ag with class I MHC. When activated, this hybridoma expresses lacZ, allowing a simple colorimetric measurement of Ag-specific T cell stimulation. We demonstrated that bone marrow cells stimulated by IL-3 in vivo and in vitro exhibited significantly increased presentation of exogenous OVA linked to beads. Lysate from OVA-transfected line 1 murine lung adenocarcinoma cells (line 1/OVA) was also presented by IL-3-stimulated bone marrow cells, suggesting that these APC can process tumor fragments or debris. Studies using TAP1/2-deficient mice and Ag presentation inhibitors indicate that this exogenous Ag presentation is mediated via the conventional class I MHC pathway. Adoptive transfer of IL-3-stimulated bone marrow cells pulsed with lysate from line 1/OVA tumor cells into naive recipient mice led to the generation of a potent CTL response. These observations indicate that use of such cells may provide a new avenue for development of tumor vaccines.
authors.affiliation: Department of Microbiology and Immunology and Cancer Center Immunology Program, University of Rochester School of Medicine and Dentistry, NY 14642, USA.
authors.forename: K Y
authors.initials: KY
authors.lastname: Yeh
authors.forename: A J
authors.initials: AJ
authors.lastname: McAdam
authors.forename: B A
authors.initials: BA
authors.lastname: Pulaski
authors.forename: N
authors.initials: N
authors.lastname: Shastri
authors.forename: J G
authors.initials: JG
authors.lastname: Frelinger
authors.forename: E M
authors.initials: EM
authors.lastname: Lord
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects / Q000276:immunology*; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D007377:Interleukin-3 / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D015395:Histocompatibility Antigens Class I; D007377:Interleukin-3; D011994:Recombinant Proteins; D010047:Ovalbumin